全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用:99美元

查看量下载量

相关文章

更多...
Core Evidence  2008 

Arzoxifene: the evidence for its development in the management of breast cancer

Full-Text   Cite this paper   Add to My Lib

Abstract:

Lee R. Jackson1, Kwok L. Cheung1, Aman U. Buzdar2, John F. R. Robertson11Professorial Unit of Surgery, Nottingham City Hospital, Nottingham, UK; 2The University of Texas, M.D. Anderson Cancer Center, Houston, Texas, USAIntroduction: Endocrine therapy is an important and integral part of breast cancer management. Selective estrogen receptor modulators (SERMs), such as tamoxifen, remain a vital component in the endocrine therapy armamentarium. However the “ideal SERM”, which has antagonist effects on the breast and endometrium but beneficial agonistic effects on bone and lipid profile, remains to be found.Aim: The aim of this review is to examine the evidence for arzoxifene as the “ideal SERM.”Evidence review: Arzoxifene showed initial promise as the “ideal SERM” in preclinical, phase I, and phase II clinical studies. It appeared to have powerful antiestrogenic effects on breast cancer and endometrium, with equally strong favorable estrogenic effects on bone and lipid profile, minimal side effects, and good oral bioavailability. However, phase III trial data found it to be inferior to tamoxifen, bringing an apparent end to its investigation as a breast cancer treatment. Clinical potential: Despite early promise as the “ideal SERM”, results from a phase III trial have relegated arzoxifene to research in breast cancer prevention and osteoporosis treatment.Key words: arzoxifene, selective estrogen receptor modulators (SERM), breast cancer

Full-Text

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133